公开(公告)号：US4695536A

公开(公告)日：1987-09-22

申请号：US569609

申请日：1984-01-10

申请人： Richard L. Lindstrom ,  Donald J. Doughman ,  Debra Skelnik

发明人： Richard L. Lindstrom ,  Donald J. Doughman ,  Debra Skelnik

IPC分类号： A01N1/02

CPC分类号： A01N1/02 ,  A01N1/0263

摘要： A universal tissue preservation system including a storage container and a preservation media for corneal and other tissue storage. The universal corneal preservation system provides for closed system storage (media not changed) at 4.degree. centigrade under refrigeration for 1-14 days or 34.degree. centigrade storage in an incubator for at least 35 days (five weeks). The storage system provides for a quarantine technique insuring sterility, and a special media for maintaining cell viability and corneal deturgescence, (normal thickness). The corneal storage container provides for endothelial cell photography and media sampling. The preservation media can also be utilized in an open batch technique (media changed at regular intervals) for storage of corneas over one year. In addition, the preservation media can be used as an intraocular irrigation fluid during surgery.

摘要翻译： 一种通用组织保存系统，包括储存容器和用于角膜和其他组织储存的保存介质。 通用角膜保存系统在4℃冷藏下保存1-14天或34摄氏度的封闭系统储存（培养基未改变），保存至少35天（5周）。 存储系统提供保证无菌性的隔离技术，以及维持细胞活力和角膜去斑的特殊介质（正常厚度）。 角膜储存容器提供内皮细胞摄影和介质取样。 保存介质也可以在一年内用于保存角膜的开放批量技术（定期更换介质）中使用。 此外，保存介质可以在手术期间用作眼内灌洗液。

公开(公告)号：US4725586A

公开(公告)日：1988-02-16

申请号：US836156

申请日：1986-03-04

申请人： Richard L. Lindstrom ,  Debra Skelnik

发明人： Richard L. Lindstrom ,  Debra Skelnik

IPC分类号： A61K31/715 ,  A61K9/00 ,  A61K31/70

CPC分类号： A61K9/0048

摘要： A surgical or irrigation solution which provides the anterior and posterior chamber of the eye with protection during surgical procedures that require irrigation. This irrigation solution is composed of a HEPES buffered Eagle's Minimum Essential Media (MEM) with Earle's Salts, without phenol red, supplemented with mixed isomers of 99% pure, chondroitin sulfate, MEM non-essential amino acids, 2-mercaptoethanol, and sodium pyruvate. Other solutions include a balanced salt solution, chondroitin sulfate, buffers and 2-mercaptoethanol. The solution can also be used in other surgical or medical applications.

摘要翻译： 一种手术或灌洗液，其在需要灌洗的手术过程中提供眼睛的前房和后房保护。 该灌注溶液由具有Earle Salts的HEPES缓冲的Eagle's Minimum Essential Media（MEM），不含酚红，补充99％纯度的混合异构体，硫酸软骨素，MEM非必需氨基酸，2-巯基乙醇和丙酮酸钠 。 其他溶液包括平衡盐溶液，硫酸软骨素，缓冲液和2-巯基乙醇。 该解决方案也可用于其他手术或医疗应用。

公开(公告)号：US5407669A

公开(公告)日：1995-04-18

申请号：US845660

申请日：1992-03-04

申请人： Richard L. Lindstrom ,  Debra Skelnik

发明人： Richard L. Lindstrom ,  Debra Skelnik

IPC分类号： A01N1/02 ,  A61K31/715 ,  A61K38/17 ,  A61K31/74 ,  C12N5/00

CPC分类号： A01N1/0226 ,  A01N1/021 ,  A01N1/0215

摘要： A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements which maintains and enhances the preservation of eye tissues, including human corneal tissues at low temperatures (2.degree. C. to 15.degree. C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing components, antibiotic(s), ATP precursors and nutrient cell supplements.

摘要翻译： 一种用于眼科应用的定义的无血液药物溶液，其含有一种或多种细胞营养补充剂，其在低温（2℃至15℃）下维持并增强眼组织的保存，包括人角膜组织。 该溶液由限定的水性营养物和电解质溶液组成，补充有糖胺聚糖，一种或多种防腐剂，能量源，缓冲系统，抗氧化剂，膜稳定剂 组分，抗生素，ATP前体和营养细胞补充剂。

公开(公告)号：US5204325A

公开(公告)日：1993-04-20

申请号：US695332

申请日：1991-05-03

申请人： Richard L. Lindstrom ,  Debra Skelnik

发明人： Richard L. Lindstrom ,  Debra Skelnik

IPC分类号： A61K38/18

CPC分类号： A61K38/28 ,  A61K38/1808

摘要： Viscoelastic solution including a buffered solution, 0.01-8% chondroitin sulfate, 0.1-8% hydroxypropyl methylcellulose, pH adjusted to 6.0-8.0 at a osmolality between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimum essential media (MEM), phosphate buffer saline (PBS), buffered balanced salt solution, or TC199. A cell growth factor or cell growth supplement is included in the solution.

摘要翻译： 包含缓冲溶液的粘弹性溶液，0.01-8％硫酸软骨素，0.1-8％羟丙基甲基纤维素，在200-400mOsmol / L的重量摩尔渗透压浓度下将pH调节至6.0-8.0。 缓冲溶液可以是HEPES缓冲的最小必需培养基（MEM），磷酸盐缓冲盐水（PBS），缓冲平衡盐溶液或TC199。 细胞生长因子或细胞生长补充剂包括在溶液中。

公开(公告)号：US5013714A

公开(公告)日：1991-05-07

申请号：US284533

申请日：1988-12-15

申请人： Richard L. Lindstrom ,  Debra Skelnik

发明人： Richard L. Lindstrom ,  Debra Skelnik

IPC分类号： A61K38/18

CPC分类号： A61K38/28 ,  A01N1/0226 ,  A61K38/1808 ,  Y10S514/912

摘要： Viscoelastic solution including a buffered solution, 0.01-8% chondroitin sulfate, 0.1-8% hydroxypropyl methylcellulose, pH adjusted to 6.0-8.0 at a osmolality between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimum essential media (MEM), phosphate buffer saline (PBS), buffered balanced salt solution, or TC199. A cell growth factor or cell growth supplement is included in the solution.

摘要翻译： 包含缓冲溶液的粘弹性溶液，0.01-8％硫酸软骨素，0.1-8％羟丙基甲基纤维素，在200-400mOsmol / L的重量摩尔渗透压浓度下将pH调节至6.0-8.0。 缓冲溶液可以是HEPES缓冲的最小必需培养基（MEM），磷酸盐缓冲盐水（PBS），缓冲平衡盐溶液或TC199。 细胞生长因子或细胞生长补充剂包括在溶液中。

公开(公告)号：US5366964A

公开(公告)日：1994-11-22

申请号：US434305

申请日：1989-11-13

申请人： Richard L. Lindstrom ,  Debra Skelnik

发明人： Richard L. Lindstrom ,  Debra Skelnik

IPC分类号： A61K38/18 ,  A61K31/715

CPC分类号： A61K38/28 ,  A01N1/0226 ,  A61K38/1808 ,  Y10S514/912

摘要： A viscoelastic solution including a buffered solution, 0.01-10% chondroitin sulfate, 0.01-10% hydroxypropyl methylcellulose, and 0.01-10% sodium hyaluronate, pH adjusted to 6.0-8.0 at a osmolarity between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimal essential medium (MEM), phosphate buffered saline (PBS), or buffered balanced salt solution. A cell growth factor or cell growth supplement can also be included in the solution.

摘要翻译： 包含缓冲溶液，0.01-10％硫酸软骨素，0.01-10％羟丙基甲基纤维素和0.01-10％透明质酸钠的粘弹性溶液，在200-400mOsmol / L的渗透压下pH调节至6.0-8.0。 缓冲溶液可以是HEPES缓冲的最小必需培养基（MEM），磷酸盐缓冲盐水（PBS）或缓冲平衡盐溶液。 细胞生长因子或细胞生长补充剂也可以包括在溶液中。

公开(公告)号：US5104787A

公开(公告)日：1992-04-14

申请号：US487919

申请日：1990-03-05

申请人： Richard L. Lindstrom ,  Debra Skelnik

发明人： Richard L. Lindstrom ,  Debra Skelnik

IPC分类号： A01N1/02 ,  A61F9/007 ,  A61K9/08

CPC分类号： A01N1/0226

摘要： A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements which maintains and enhances the preservation of eye tissues, including human corneal tissues at low temperatures (2.degree. C. to 15.degree. C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing components, antibiotic(s), ATP precursors and nutrient cell supplements.

摘要翻译： 一种用于眼科应用的定义的无血液药物溶液，其含有一种或多种细胞营养补充剂，其在低温（2℃至15℃）下维持并增强眼组织的保存，包括人角膜组织。 该溶液由限定的水性营养物和电解质溶液组成，补充有糖胺聚糖，一种或多种防腐剂，能量源，缓冲系统，抗氧化剂，膜稳定剂 组分，抗生素，ATP前体和营养细胞补充剂。

公开(公告)号：US09943401B2

公开(公告)日：2018-04-17

申请号：US12384659

申请日：2009-04-06

申请人： Eugene de Juan, Jr. ,  Cary J. Reich ,  Stephen Boyd ,  Yair Alster ,  David Sierra ,  Hanson S. Gifford ,  Jose D. Alejandro ,  Richard L. Lindstrom ,  K. Angela Macfarlane ,  Douglas Sutton ,  John Anthony Scholl

发明人： Eugene de Juan, Jr. ,  Cary J. Reich ,  Stephen Boyd ,  Yair Alster ,  David Sierra ,  Hanson S. Gifford ,  Jose D. Alejandro ,  Richard L. Lindstrom ,  K. Angela Macfarlane ,  Douglas Sutton ,  John Anthony Scholl

IPC分类号： A61F2/14 ,  A61F9/00 ,  G02C7/04

CPC分类号： A61F2/142 ,  A61F2/14 ,  A61F9/00 ,  A61F2250/0067 ,  G02C7/047

摘要： A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.

公开(公告)号：US5002569A

公开(公告)日：1991-03-26

申请号：US529883

申请日：1990-05-29

申请人： Richard L. Lindstrom

发明人： Richard L. Lindstrom

IPC分类号： A61F2/16

CPC分类号： A61F2/1613

摘要： An intraocular lens denoted as a YAG dimpled lens or dimpled YAG lens, which includes a barrier rim and a YAG spacer area in a posterior surface of the lens. The barrier rim is 2-4 mm in longitudinal length and the YAG spacer is 3-4 mm in longitudinal length across the surface diameter of an optic of the intraocular lens. The lens optic can be either plano-convex or bi-convex. A cutout for the dimpled YAG spacer is provided which is either a convave or a substantially rectangular geometrical configuration in the posterior surface of the lens. The YAG spacer can also include a trough or a groove geometrical configuration, such as in the configurations of a Maltese cross, a circular trough or groove, or a circular trough or groove with a Maltese cross therein. The barrier rim is 33% to 80% of the total surface are of the posterior surface of the lens.

摘要翻译： 一种称为YAG凹凸透镜或凹凸YAG透镜的眼内透镜，其包括镜片后表面中的屏障边缘和YAG间隔区域。 屏障边缘在纵向长度上为2-4mm，并且YAG间隔物在纵向长度上穿过眼内透镜的光学元件的表面直径为3-4mm。 透镜光学元件可以是平凸的或双凸的。 提供了用于凹凸的YAG间隔件的切口，其是在镜片的后表面中的手链或基本上矩形的几何构型。 YAG间隔物还可以包括槽或凹槽几何构型，例如在马耳他十字架，圆形槽或凹槽的构造中，或者在其中具有马耳他十字的圆形槽或槽。 屏障边缘是总表面的33％至80％是透镜的后表面。

公开(公告)号：US4959319A

公开(公告)日：1990-09-25

申请号：US311846

申请日：1989-02-17

申请人： Debra L. Skelnik ,  Richard L. Lindstrom

发明人： Debra L. Skelnik ,  Richard L. Lindstrom

IPC分类号： C12N5/071

CPC分类号： C12N5/0621

摘要： A process for establishing functional human corneal tissue consisting of an enhanced contact-inhibited endothelial monolayer derived from isolated human corneal endothelial cells with other integral corneal layers remaining intact. The process is divided into four integral parts.1. Isolation of human corneal endothelial cells from donor corneas.2. Establishment of a human corneal endothelial cell line which involves the establishment of primary cell cultures, proliferation, and continued maintenance and subculturing of these cells in vitro.3. The utilization of long term storage of isolated human corneal endothelial cells at -80.degree. C.4. Utilizing these isolated corneal endothelial cells from the above processes to enhance the corneal endothelial monolayer of human donor corneas to be used for penetrating keratoplasty.Two distinct methods of corneal endothelial enhancement may be utilized. In the first method, isolated human corneal endothelial cells are incorporated into the existing donor monolayer and re-establish a contact-inhibited functional monolayer, with a flattened, hexagonal configuration. In this procedure, the donor corneal endothelium remains intact and is supplemented with additional corneal endothelium. In the second method, isolated human corneal endothelial cells are seeded onto a denuded Descement's membrane and re-establish an intact cellular matrix, and form a contact-inhibited functional endothelial monolayer. In this procedure, the donor corneal endothelium is completely removed and replaced with new endothelial cells.

摘要翻译： 用于建立功能性人角膜组织的方法，其由来自分离的人角膜内皮细胞的增强的接触抑制内皮单层组成，其余整体角膜层保持完整。 该过程分为四个组成部分。 1.从供体角膜分离人角膜内皮细胞。 2.建立人类角膜内皮细胞系，其涉及在体外建立原代细胞培养物，增殖和持续维持和传代培养这些细胞。 3.在-80℃下利用长期保存的孤立人角膜内皮细胞。4.利用上述方法分离的角膜内皮细胞，增强用于穿透角膜移植术的人供体角膜角膜内皮单层。 可以使用两种不同的角膜内皮增强方法。 在第一种方法中，将孤立的人角膜内皮细胞掺入现有的供体单层中，并重新建立具有扁平六边形构型的接触抑制功能单层。 在此过程中，供体角膜内皮保持完整，并补充额外的角膜内皮。 在第二种方法中，将分离的人角膜内皮细胞接种到裸露的Descement膜上并重新建立完整的细胞基质，并形成接触抑制功能内皮单层。 在此过程中，供体角膜内皮被完全去除，并用新的内皮细胞代替。